Patents by Inventor Hirotaka Kashiwagi
Hirotaka Kashiwagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958975Abstract: An asphalt composition containing asphalt and polyester, wherein a content of asphaltene in the asphalt is 18% by mass or more and 40% by mass or less, and a content of the polyester is 1 part by mass or more and 10 parts by mass or less with respect to 100 parts by mass of the asphalt.Type: GrantFiled: November 12, 2019Date of Patent: April 16, 2024Assignee: KAO CORPORATIONInventors: Hiroki Kakiuchi, Ryoichi Hashimoto, Hirotaka Kashiwagi
-
Publication number: 20230382912Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.Type: ApplicationFiled: August 11, 2023Publication date: November 30, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi YOSHINO, Satoshi TSUCHIYA, Atsushi MATSUO, Tsutomu SATO, Masahiro NISHIMOTO, Kyoko OGURI, Hiroko OGAWA, Yoshikazu NISHIMURA, Yoshiyuki FURUTA, Hirotaka KASHIWAGI, Nobuyuki HORI, Takuma KAMON, Takuya SHIRAISHI, Shoshin YOSHIDA, Takahiro KAWAI, Satoshi TANIDA, Masahide AOKI
-
Patent number: 11814381Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.Type: GrantFiled: October 7, 2020Date of Patent: November 14, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi Yoshino, Satoshi Tsuchiya, Atsushi Matsuo, Tsutomu Sato, Masahiro Nishimoto, Kyoko Oguri, Hiroko Ogawa, Yoshikazu Nishimura, Yoshiyuki Furuta, Hirotaka Kashiwagi, Nobuyuki Hori, Takuma Kamon, Takuya Shiraishi, Shoshin Yoshida, Takahiro Kawai, Satoshi Tanida, Masahide Aoki
-
Publication number: 20230250290Abstract: The present invention provides an asphalt modifier composed of a crystalline polyester that has a structural unit derived from an alcohol component containing a linear aliphatic alcohol and a structural unit derived from a carboxylic acid component, the crystalline polyester having a melting point of 65° C. or higher and 160° C. or lower.Type: ApplicationFiled: June 29, 2021Publication date: August 10, 2023Applicant: KAO CORPORATIONInventors: Hirotaka KASHIWAGI, Yusuke AKINO, Norihiro FUKURI
-
Publication number: 20230125029Abstract: The present invention provides an asphalt composition obtained by blending an asphalt and an addition polymerization-type polymer, the addition polymerization-type polymer having a hydroxyl value of 10 mgKOH/g or more and 60 mgKOH/g or less and having a weight average molecular weight (Mw) of 2,500 or more and 70,000 or less.Type: ApplicationFiled: March 5, 2021Publication date: April 20, 2023Applicant: KAO CORPORATIONInventors: Yusuke AKINO, Norihiro FUKURI, Hirotaka KASHIWAGI
-
Publication number: 20210395529Abstract: An asphalt composition containing asphalt and polyester, wherein a content of asphaltene in the asphalt is 18% by mass or more and 40% by mass or less, and a content of the polyester is 1 part by mass or more and 10 parts by mass or less with respect to 100 parts by mass of the asphalt.Type: ApplicationFiled: November 12, 2019Publication date: December 23, 2021Applicant: KAO CORPORATIONInventors: Hiroki KAKIUCHI, Ryoichi HASHIMOTO, Hirotaka KASHIWAGI
-
Publication number: 20210017176Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.Type: ApplicationFiled: October 7, 2020Publication date: January 21, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi YOSHINO, Satoshi TSUCHIYA, Atsushi MATSUO, Tsutomu SATO, Masahiro NISHIMOTO, Kyoko OGURI, Hiroko OGAWA, Yoshikazu NISHIMURA, Yoshiyuki FURUTA, Hirotaka KASHIWAGI, Nobuyuki HORI, Takuma KAMON, Takuya SHIRAISHI, Shoshin YOSHIDA, Takahiro KAWAI, Satoshi TANIDA, Masahide AOKI
-
Patent number: 10858356Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.Type: GrantFiled: September 26, 2017Date of Patent: December 8, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi Yoshino, Satoshi Tsuchiya, Atsushi Matsuo, Tsutomu Sato, Masahiro Nishimoto, Kyoko Oguri, Hiroko Ogawa, Yoshikazu Nishimura, Yoshiyuki Furuta, Hirotaka Kashiwagi, Nobuyuki Hori, Takuma Kamon, Takuya Shiraishi, Shoshin Yoshida, Takahiro Kawai, Satoshi Tanida, Masahide Aoki
-
Publication number: 20190225604Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.Type: ApplicationFiled: September 26, 2017Publication date: July 25, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi YOSHINO, Satoshi TSUCHIYA, Atsushi MATSUO, Tsutomu SATO, Masahiro NISHIMOTO, Kyoko OGURI, Hiroko OGAWA, Yoshikazu NISHIMURA, Yoshiyuki FURUTA, Hirotaka KASHIWAGI, Nobuyuki HORI, Takuma KAMON, Takuya SHIRAISHI, Shoshin YOSHIDA, Takahiro KAWAI, Satoshi TANIDA, Masahide AOKI
-
Patent number: 9499553Abstract: The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.Type: GrantFiled: September 14, 2015Date of Patent: November 22, 2016Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yoshihito Ohtake, Naoki Okamoto, Yoshiyuki Ono, Hirotaka Kashiwagi, Atsushi Kimbara, Takeo Harada, Nobuyuki Hori, Yoshihisa Murata, Kazutaka Tachibana, Shota Tanaka, Kenichi Nomura, Mitsuaki Ide, Eisaku Mizuguchi, Yasuhiro Ichida, Shuichi Ohtomo, Naoshi Horiba
-
Publication number: 20160002251Abstract: The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.Type: ApplicationFiled: September 14, 2015Publication date: January 7, 2016Inventors: Yoshihito OHTAKE, Naoki OKAMOTO, Yoshiyuki ONO, Hirotaka KASHIWAGI, Atsushi KIMBARA, Takeo HARADA, Nobuyuki HORI, Yoshihisa MURATA, Kazutaka TACHIBANA, Shota TANAKA, Kenichi NOMURA, Mitsuaki IDE, Eisaku MIZUGUCHI, Yasuhiro ICHIDA, Shuichi OHTOMO, Naoshi HORIBA
-
Patent number: 9221753Abstract: An object of the present invention is to provide a process for synthesizing a vitamin D compound by simple procedures at lower costs. The present invention provides a process for preparing a vitamin D compound and an intermediate thereof, comprising the step of: (a) mixing a ketone or aldehyde, a Wittig reagent, and a base; or (b) mixing a ketone or aldehyde and a Wittig reagent, and then adding a base to the resulting mixture.Type: GrantFiled: February 3, 2005Date of Patent: December 29, 2015Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hirotaka Kashiwagi, Yoshiyuki Ono
-
Patent number: 7994318Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: GrantFiled: March 18, 2010Date of Patent: August 9, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Patent number: 7935688Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: GrantFiled: June 9, 2006Date of Patent: May 3, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Tsuyoshi Haneishi, Kazuki Shimizu
-
Publication number: 20110060146Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: ApplicationFiled: November 15, 2010Publication date: March 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: TADAKATSU TAKAHASHI, YOSHIYUKI ONO, HIROTAKA KASHIWAGI, TSUYOSHI HANEISHI, KAZUKI SHIMIZU
-
Patent number: 7872142Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: GrantFiled: March 18, 2010Date of Patent: January 18, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Publication number: 20100197917Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: ApplicationFiled: March 18, 2010Publication date: August 5, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Publication number: 20100174076Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: ApplicationFiled: March 18, 2010Publication date: July 8, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Patent number: 7709664Abstract: Novel compounds composition capable of inhibiting TNF? and having anti immunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.Type: GrantFiled: September 13, 2005Date of Patent: May 4, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
-
Publication number: 20090137609Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.Type: ApplicationFiled: June 9, 2006Publication date: May 28, 2009Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tadakatsu Takahashi, Yoshiyuki Ono, Hirotaka Kashiwagi, Tsuyoshi Haneishi, Kazuki Shimizu